GlaxoSmithKline (GSK) Upgraded to “Buy” at Beaufort Securities

Beaufort Securities upgraded shares of GlaxoSmithKline (LON:GSK) to a buy rating in a report released on Thursday morning. They currently have GBX 1,500 ($21.03) target price on the stock, up from their prior target price of GBX 1,450 ($20.33).

A number of other analysts have also commented on the company. Societe Generale reissued a sell rating on shares of GlaxoSmithKline in a report on Thursday, November 9th. Berenberg Bank reduced their target price on GlaxoSmithKline from GBX 1,835 ($25.73) to GBX 1,760 ($24.68) and set a buy rating for the company in a report on Thursday, November 2nd. Morgan Stanley set a GBX 1,450 ($20.33) target price on GlaxoSmithKline and gave the company a sell rating in a report on Monday, November 6th. Deutsche Bank set a GBX 1,610 ($22.57) target price on GlaxoSmithKline and gave the company a neutral rating in a report on Friday, October 27th. Finally, Barclays reaffirmed an equal weight rating and issued a GBX 1,450 ($20.33) target price on shares of GlaxoSmithKline in a report on Friday, October 27th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company’s stock. GlaxoSmithKline currently has a consensus rating of Hold and an average target price of GBX 1,541.36 ($21.61).

Shares of GlaxoSmithKline (LON GSK) traded down GBX 15.40 ($0.22) on Thursday, reaching GBX 1,288.40 ($18.07). The company’s stock had a trading volume of 8,051,208 shares, compared to its average volume of 9,220,000. The company has a market cap of $64,140.00 and a price-to-earnings ratio of 4,156.13. GlaxoSmithKline has a 1 year low of GBX 1,235.20 ($17.32) and a 1 year high of GBX 1,724.50 ($24.18).

In related news, insider Sir Roy Anderson bought 562 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were purchased at an average price of GBX 1,278 ($17.92) per share, for a total transaction of £7,182.36 ($10,070.61). Also, insider Patrick Vallance sold 20,000 shares of the stock in a transaction on Monday, December 18th. The stock was sold at an average price of GBX 1,310 ($18.37), for a total value of £262,000 ($367,358.38). In the last 90 days, insiders have acquired 581 shares of company stock worth $743,284.

COPYRIGHT VIOLATION WARNING: “GlaxoSmithKline (GSK) Upgraded to “Buy” at Beaufort Securities” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://sportsperspectives.com/2018/02/09/glaxosmithkline-gsk-upgraded-to-buy-at-beaufort-securities.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply